摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

乙酮,1-(4-丙基-1-哌嗪基)- | 91086-21-4

中文名称
乙酮,1-(4-丙基-1-哌嗪基)-
中文别名
1-(4-丙基哌嗪-1-基)乙酮
英文名称
N-Propyl-N'-acetyl-piperazin
英文别名
1-acetyl-4-propyl-piperazine;1-(4-Propylpiperazin-1-yl)ethan-1-one;1-(4-propylpiperazin-1-yl)ethanone
乙酮,1-(4-丙基-1-哌嗪基)-化学式
CAS
91086-21-4
化学式
C9H18N2O
mdl
MFCD20390373
分子量
170.255
InChiKey
KOOLYPVFWPPNBC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.4
  • 重原子数:
    12
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.888
  • 拓扑面积:
    23.6
  • 氢给体数:
    0
  • 氢受体数:
    2

文献信息

  • COMBINATION OF KINASE INHIBITORS AND USES THEREOF
    申请人:INTELLIKINE, LLC
    公开号:US20150030588A1
    公开(公告)日:2015-01-29
    The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or a receptor tyrosine kinase (RTK) in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or an RTK in a subject. In yet another aspect, a method of inhibiting phosphorylation of Akt (S473) in a cell is set forth.
    本发明提供了一种治疗与PI3-激酶a和/或受体酪氨酸激酶(RTK)有关的疾病状况的方法。另一方面,该发明提供了一种治疗与PI3-激酶α和/或受体酪氨酸激酶(RTK)有关的疾病状况的方法。另一方面,提出了一种抑制细胞中Akt(S473)磷酸化的方法。
  • 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION
    申请人:Wakamoto Pharmaceutical Co., Ltd.
    公开号:EP1820799A1
    公开(公告)日:2007-08-22
    The present invention has its object to provide a 2,3,4,5-tetrahydro-1H-1,5-benzodiazepine derivative represented with the Formula (1) , or the pharmaceutically acceptable salt, which is effective as a therapeutic and prophylactic agent for diabetes, diabetic nephropathy, or glomerulosclerosis.
    本发明的目的是提供一种用化学式(1)表示的2,3,4,5-四氢-1H-1,5-苯二氮䓬衍生物,或其药学上可接受的盐,作为治疗和预防糖尿病、糖尿病肾病或肾小球硬化的药剂。
  • [EN] CXCR3 RECEPTOR AGONISTS<br/>[FR] AGONISTES DU RÉCEPTEUR CXCR3
    申请人:CELGENE INT II SARL
    公开号:WO2018045246A1
    公开(公告)日:2018-03-08
    Compounds are provided having the structure of the following Formula I: where R, R1, R2, R3a and R3b are as defined herein. Pharmaceutical compositions comprising such compounds, as well as methods related to their manufacture and use, are also provided.
    提供具有以下式I结构的化合物:其中R、R1、R2、R3a和R3b如本文所述定义。还提供了包含这些化合物的药物组合物,以及与它们的制造和使用相关的方法。
  • HETEROCYCLIC COMPOUNDS AND USES THEREOF
    申请人:Intellikine LLC
    公开号:US20150320727A1
    公开(公告)日:2015-11-12
    Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.
    本文描述了调节PI3激酶活性的杂环实体、含有这些杂环实体的药物组合物,以及利用这些化学实体治疗与PI3激酶活性相关的疾病和症状的方法。
  • SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS
    申请人:Bignan Gilles
    公开号:US20110294780A1
    公开(公告)日:2011-12-01
    The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.
    本发明涉及式(I)的化合物,制备这些化合物的方法,组合物,中间体及其衍生物,并用于治疗包括但不限于强直性脊柱炎,动脉粥样硬化,关节炎(如类风湿关节炎,感染性关节炎,儿童关节炎,银屑病性关节炎,反应性关节炎),与骨相关的疾病(包括与骨形成有关的疾病),乳腺癌(包括对抗雌激素治疗无效的癌症),心血管疾病,软骨相关疾病(如软骨损伤/丧失,软骨退化以及与软骨形成有关的疾病),软骨发育不良,软骨肉瘤,慢性腰部损伤,慢性支气管炎,慢性炎症性气道疾病,慢性阻塞性肺疾病,糖尿病,能量稳态紊乱,痛风,假性痛风,脂质紊乱,代谢综合征,多发性骨髓瘤,肥胖,骨关节炎,遗传性骨发育不全,骨溶解性骨转移,软骨软化症,骨质疏松症,帕金森病,牙周病,多肌痛风,Reiter综合征,重复性应激损伤,高血糖,血糖水平升高和胰岛素抵抗等病症的方法。
查看更多